DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
PTC299 is an investigational drug.
There have been 7 clinical trials for PTC299. The most recent clinical trial was a Phase 1 trial, which was initiated on July 9th 2020.
The most common disease conditions in clinical trials are Nervous System Neoplasms, Pneumonia, and Sarcoma, Kaposi. The leading clinical trial sponsors are PTC Therapeutics, United States Department of Defense, and National Cancer Institute (NCI).
There are nine US patents protecting this investigational drug and sixty international patents.
Recent Clinical Trials for PTC299
|A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19)||PTC Therapeutics||Phase 2/Phase 3|
|Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias||PTC Therapeutics||Phase 1|
|PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors||National Cancer Institute (NCI)||Phase 1|
Top disease conditions for PTC299
Top clinical trial sponsors for PTC299
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|PTC299||⤷ Try it Free||Carboline derivatives useful in the inhibition of angiogenesis||PTC Therapeutics, Inc. (South Plainfield, NJ)||⤷ Try it Free|
|PTC299||⤷ Try it Free||Carboline derivatives useful in the treatment of cancer||PTC Therapeutics, Inc. (South Planfield, NJ)||⤷ Try it Free|
|PTC299||⤷ Try it Free||Administration of carboline derivatives useful in the treatment of cancer and other diseases||PTC Therapeutics, Inc. (South Plainfield, NJ)||⤷ Try it Free|
|PTC299||⤷ Try it Free||Inhibition of VEGF translation||PTC Therapeutics, Inc. (South Plainfield, NJ)||⤷ Try it Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|PTC299||Austria||AT547102||2024-03-15||⤷ Try it Free|
|PTC299||Australia||AU2005222632||2024-03-15||⤷ Try it Free|
|PTC299||Brazil||BRPI0508814||2024-03-15||⤷ Try it Free|
|PTC299||Canada||CA2559408||2024-03-15||⤷ Try it Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|